Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction and other diseases or symptoms

1. A method of treating or alleviating lower urinary tract symptoms (LUTS), comprising administrating a composition comprising dried cranberry powder,

wherein the composition is enriched in cranberry seeds or cranberry seed meal,

wherein the cranberry seeds or cranberry seed meal are present in the therapeutic composition in an amount of about 15% to about 25% by weight of the dried cranberry powder

wherein the composition comprises about 5% to 12% of organic acids by weight,

wherein the composition is administered at a daily dose of between 250 to 500 mg;

wherein the daily dose of organic acids is less than about 12.5 to 60 mg;

wherein the daily dose of anthocyanins is less than about 0.175 mg to 0.75 mg;

wherein the daily dose of proanthocyanidins is less than about 0.5 mg to 7.5 mg; and

wherein the daily dose of the total phenolics is less than about 4.25 mg to 16.25 mg.

2. The method of claim 1 , wherein the cranberry is Vaccinium macrocarpon.

3. The method of claim 1 , wherein the cranberry is Vaccinium microcarpon.

4. The method of claim 1 , wherein the cranberry is Vaccinium oxycoccus.

5. The method of claim 1 , wherein the cranberry seeds or cranberry seed meal are present in the composition in an amount of about 20% by weight of the dried cranberry powder.

6. The method of claim 1 , wherein the composition comprises less than about 5% to 10% of organic acids by weight.

7. The method of claim 1 , wherein the composition comprises less than about 15% of sugars by weight.

8. The method of claim 1 , wherein the composition comprises from about 1% to about 5% of quinic acid by weight.

9. The method of claim 1 , wherein the composition comprises from about 2.2% to about 3.2% of quinic acid by weight.

10. The method of claim 1 , wherein the composition comprises from about 0.4% to about 4% of malic acid by weight.

11. The method of claim 1 , wherein the composition comprises from about 0.8% to about 1.8% of malic acid by weight.

12. The method of claim 1 , wherein the composition comprises from about 1% to about 5% of citric acid by weight.

13. The method of claim 12 , wherein the composition comprises from about 1.8% to about 3.2% of citric acid by weight.

14. The method of claim 1 , wherein the composition comprises: 0.5% to 5.0% proanthocyanidins, 0.05% to 1.5% quercetin, 0.001% to 0.1% quercetin-3-glucoside, 0.001% to 0.1% quercetin-3-rhamnoside, 0.001% to 0.1% quercetin-3-xyloside, 0.001% to 0.1% quercetin-3-arabinoside, 0.001% to 0.5% myricetin, 0.001% to 0.1% peonidin-3-galactoside, 0.001% to 0.1% peonidin-3-glucoside, 0.001% to 0.1% peonidin-3-arabinoside, 0.001% to 0.1% cyanidin-3-glucoside, 0.001% to 0.1% cyanidin-3-galactoside, 0.001% to 0.1% cyanidin-3-arabinoside, 0.001% to 0.1% protocatechuic acid 0.001% to 0.1% p-coumaric acid, 0.001% to 0.1% caffeoyl-glucoside, 0.001% to 0.1% coumaroyl-glucoside, 0.001% to 0.1% cafeic acid, 0.001% to 0.1% chlorogenic acid or 0.01 to 1.5% ursolic acid by weight.

15. The method of claim 14 , wherein the composition comprises: 1.0% to 1.2% proanthocyanidins, 0.16% to 0.20% quercetin, 0.07% to 0.09% quercetin-3-glucoside, 0.03% to 0.04% quercetin-3-rhamnoside, 0.019% to 0.025% quercetin-3-xyloside, 0.025% to 0.035% quercetin-3-arabinoside, 0.010% to 0.014% myricetin, 0.022% to 0.030% peonidin-3-galactoside, 0.0025% to 0.0035% peonidin-3-glucoside, 0.010% to 0.020% peonidin-3-arabinoside, 0.0005% to 0.0015% cyanidin-3-glucoside, 0.015% to 0.030% cyanidin-3-galactoside, 0.010% to 0.025% cyanidin-3-arabinoside, 0.019% to 0.025% protocatechuic acid, 0.04% to 0.06% p-coumaric acid, 0.015% to 0.025% caffeoyl-glucoside, 0.005% to 0.015% coumaroyl-glucoside, 0.010% to 0.015% cafeic acid or 0.030% to 0.04% chlorogenic acid by weight.

16. The method of claim 1 , wherein the composition comprises 1 to 100 μg lariciresinol, 1 to 100 μg secoisolariciresinol or 1 to 100 μg pinoresinol per 100 g of the composition by weight.

17. The method of claim 1 , wherein the composition comprises about 51 μg lariciresinol, about 12 μs secoisolariciresinol or about 78 μg pinoresinol per 100 g of the composition by weight.

18. The method of claim 1 , wherein the composition is in a solid oral dosage form.

19. The method of claim 1 , wherein the composition is administered at a daily dose of 250 mg.

20. The method of claim 1 , wherein the composition is administered at a daily dose of 500 mg.